Literature DB >> 33029707

Enhanced axillary assessment using intradermally injected microbubbles and contrast-enhanced ultrasound (CEUS) before neoadjuvant systemic therapy (NACT) identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relevant.

Karina Cox1, Nicky Dineen2, Sian Taylor-Phillips3, Nisha Sharma4, Catherine Harper-Wynne5, Deborah Allen2, Jennifer Weeks2, Ritchie Chalmers2, Deepika Akolekar2, Russell Burcombe5, Rema Jyothirmayi5, Ali Sever6.   

Abstract

PURPOSE: The purpose of this study is to measure pre-treatment diagnostic yield of malignant lymph nodes (LN) using contrast-enhanced ultrasound (CEUS) in addition to B-mode axillary ultrasound and compare clinicopathological features, response to NACT and long-term outcomes of patients with malignant LN detected with B-mode ultrasound versus CEUS.
METHODS: Between August 2009 and October 2016, NACT patients were identified from a prospective database. Follow-up data were collected until May 2019.
RESULTS: 288 consecutive NACT patients were identified; 77 were excluded, 110 had malignant LN identified by B-mode ultrasound (Group A) and 101 patients with negative B-mode axillary ultrasound had CEUS with biopsy of sentinel lymph nodes (SLN). In two cases CEUS failed. Malignant SLN were identified in 35/99 (35%) of B-mode ultrasound-negative cases (Group B). Patients in Group A were similar to those in Group B in age, mean diagnostic tumour size, grade and oestrogen receptor status. More Group A patients had a ductal phenotype. In the breast, 34 (31%) Group A patients and 8 (23%) Group B patients achieved a pathological complete response (PCR). In the axilla, 41 (37%) and 13 (37%) Groups A and B patients, respectively, had LN PCR. The systemic relapse rate was not statistically different (5% and 16% for Groups A and B, respectively).
CONCLUSIONS: Enhanced assessment with CEUS before NACT identifies patients with axillary metastases missed by conventional B-mode ultrasound. Without CEUS, 22 (63%) of cases in Group B (negative B-mode ultrasound) may have been erroneously classed as progressive disease by surgical SLN excision after NACT.

Entities:  

Keywords:  Axilla; Axillary imaging; B-mode ultrasound; Contrast-enhanced ultrasound; Lymph node metastases; Neoadjuvant systemic therapy; Sentinel lymph nodes

Mesh:

Substances:

Year:  2020        PMID: 33029707     DOI: 10.1007/s10549-020-05956-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  2 in total

1.  3D Super-Resolution US Imaging of Rabbit Lymph Node Vasculature in Vivo by Using Microbubbles.

Authors:  Jiaqi Zhu; Ethan M Rowland; Sevan Harput; Kai Riemer; Chee Hau Leow; Brett Clark; Karina Cox; Adrian Lim; Kirsten Christensen-Jeffries; Ge Zhang; Jemma Brown; Christopher Dunsby; Robert J Eckersley; Peter D Weinberg; Meng-Xing Tang
Journal:  Radiology       Date:  2019-04-16       Impact factor: 11.105

Review 2.  Axillary Nodal Staging with Contrast-Enhanced Ultrasound.

Authors:  Nisha Sharma; Karina Cox
Journal:  Curr Breast Cancer Rep       Date:  2017-11-04
  2 in total
  1 in total

1.  Indocyanine Green Fluorescence-Guided Sentinel Node Biopsy in Breast Cancer Within a North African Population: A Retrospective Study.

Authors:  Samir Hidar; Amal Alimi; Abdejlil Khlifi; Selma Chachia; Ons Kaabia; Sassi Bouguizane; Mohamed Bibi; Hédi Khairi
Journal:  Eur J Breast Health       Date:  2021-10-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.